Skip to main content
Premium Trial:

Request an Annual Quote

Aviva to Make Antibodies for ISB's Liver Toxicity Biomarker Program

NEW YORK (GenomeWeb News) - Aviva Systems Biology will produce antibodies that the Institute for Systems Biology will use to identify liver toxicity biomarkers, Aviva said Wednesday.
 
Under the terms of the collaborative agreement, Aviva will develop and produce the antibodies from a list of proteins provided by the ISB.
 
ISB will then assess the efficacy of these antibodies and will use them to find biomarker proteins that work as early liver toxicity biomarkers.
 
Aviva said the antibodies will be used in surface plasmon resonance imaging, a method of detecting proteins at density levels lower than is currently possible with mass spectrometry and other technologies.
 
Aviva said it has an inventory of more than 12,000 target peptide-specific antibodies that represent over 4,000 human and mouse targets.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.